Maternal low molecular weight heparin versus sildenafil citrate for fetal growth restriction: a randomized, parallel groups, open-label clinical trial
| Autor: | Radwa Rasheedy, R Tarek, G El Bishry |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Randomization Sildenafil medicine.drug_class Birth weight Urology Low molecular weight heparin law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law 030225 pediatrics medicine 030212 general & internal medicine Pregnancy business.industry Obstetrics and Gynecology Heparin medicine.disease chemistry Pediatrics Perinatology and Child Health Gestation business medicine.drug |
| Zdroj: | Journal of Perinatology. 40:715-723 |
| ISSN: | 1476-5543 0743-8346 |
| DOI: | 10.1038/s41372-019-0544-1 |
| Popis: | To compare the effect of sildenafil citrate (SC) and low molecular weight heparin (LMWH) on neonatal birth weight (BW) and the fetoplacental blood flow in pregnancies with FGR. A parallel groups, randomized clinical trial was conducted at a university hospital, between June 2017 and September 2018, involving 100 pregnant women with placental mediated FGR between 28 and 35 weeks of gestation who were randomly assigned to receive either SC or LMWH started at FGR diagnosis till delivery. The neonatal BW in LMWH group was higher than SC group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink